Vanguard Global Advisers
LYEL icon

Vanguard Global Advisers’s Lyell Immunopharma LYEL Stock Holding History

Vanguard Global Advisers’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$72.6K Hold
5,165
– – ﹤0.01% 2933
2026
Q1 		$104K Buy
+5,165
New +$121K ﹤0.01% 2713

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

Vanguard Global Advisers's LYEL Position: Q2 2026 in Review

Vanguard Global Advisers held its Lyell Immunopharma (LYEL) position steady in Q2 2026 at 5,165 shares worth $72.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2933.

Vanguard Global Advisers first reported a position in LYEL in Q1 2026 and has held it in 2 quarters since. The position peaked at $104K in Q1 2026. 86 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Vanguard Global Advisers held 5,165 shares of Lyell Immunopharma worth $72.6K as of Q2 2026.
  • Vanguard Global Advisers left its Lyell Immunopharma share count unchanged in Q2 2026.
  • Lyell Immunopharma made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2933 holding.
  • Vanguard Global Advisers first reported a position in Lyell Immunopharma in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Lyell Immunopharma position peaked at $104K in Q1 2026.
  • 86 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.